Publications by authors named "Shrushma Loi"
Article Synopsis
- The study aimed to compare the effectiveness of 6 months versus 12 months of adjuvant trastuzumab in treating HER2-positive early breast cancer, with the main goal of determining if the shorter duration was as effective in preventing disease recurrence after 4 years.
- Conducted as a Phase III randomized controlled trial across 152 NHS hospitals, it involved 4,088 patients who were randomly assigned to receive either 6 or 12 months of trastuzumab treatment alongside chemotherapy.
- The primary outcome measured was disease-free survival, while secondary outcomes included overall survival, cost-effectiveness, and cardiac function, with an emphasis on showing that the shorter treatment duration remains within a non-inferiority
STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis.
BMJ Open
November 2019
Introduction: Imbalance of the gut microbiome is key to the pathogenesis of ulcerative colitis (UC). Faecal microbiota transplant (FMT) is the transfer of homogenised and filtered faeces from a healthy individual to the gastrointestinal tract of a patient with disease. Published datasets show a positive signal for the use of FMT to treat UC, but the optimal route and dose of FMT remain unanswered.
View Article and Find Full Text PDFArticle Synopsis
- A study investigated whether a shorter 6-month treatment of trastuzumab for HER2-positive early breast cancer is as effective as the standard 12-month treatment in improving disease-free survival.
- This was a large, randomized trial involving over 4,000 patients from 152 centers in the UK, comparing the two treatment durations.
- Results showed that the 4-year disease-free survival rates were similar for both groups, with 89.4% for the 6-month treatment and 89.8% for the 12-month treatment, indicating that shorter treatment could be a viable option.
Background: Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In this trial there will be a trade-off between a possible small decrease in disease-free survival (DFS) with 6-months and reduced cardiotoxicity and cost.
View Article and Find Full Text PDFBackground: We report cardiac events in the Persephone trial which compares 6-12 months of adjuvant trastuzumab in women with confirmed HER2-positive, early-stage breast cancer.
Methods: Clinical cardiac events were defined as any of the following: symptoms and/or signs of congestive heart failure (CHF) and new or altered CHF medication. In addition, left ventricular ejection fraction (LVEF) was measured at baseline and then 3 monthly for 12 months.